145 related articles for article (PubMed ID: 8632572)
1. A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer.
Debruyne FM; Dijkman GA; Lee DC; Witjes WP; del Moral F; Karthaus HF; van der Mejden AP; Plasman JW; Pull HC; Kums JJ; Idema JG; Hoefakker JW; Heijbroek RP; Kil PJ; Khoe GS
J Urol; 1996 Apr; 155(4):1352-4. PubMed ID: 8632572
[TBL] [Abstract][Full Text] [Related]
2. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer.
Oefelein M
J Urol; 2003 Jan; 169(1):251-5. PubMed ID: 12478147
[TBL] [Abstract][Full Text] [Related]
3. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer.
Sarosdy MF; Schellhammer PF; Soloway MS; Vogelzang NJ; Crawford ED; Presti J; Chodak GW; Mitchell P; Porter L
BJU Int; 1999 May; 83(7):801-6. PubMed ID: 10368200
[TBL] [Abstract][Full Text] [Related]
4. A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. The Dutch South East Cooperative Urological Group.
Dijkman GA; Debruyne FM; Fernandez del Moral P; Plasman JW; Hoefakker JW; Idema JG; Sykes M
Eur Urol; 1995; 27(1):43-6. PubMed ID: 7744141
[TBL] [Abstract][Full Text] [Related]
5. Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group.
Fernandez del Moral P; Dijkman GA; Debruyne FM; Witjes WP; Kolvenbag GJ
Urology; 1996 Dec; 48(6):894-900. PubMed ID: 8973673
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer.
Chen N; Wang Z; Chen M; Ma Q; He Y; Wang Y; Li X; Qiu M; Shi L; Zhu S; Xie Q; Liu X; Shi B; Lin G; Yang W; Liao Y; Zhang H; Wang S; Li J; Wang S; Dong L; Chen H; Lu J; Cheng Y; Zhang X; Ma L; Zhou L; Wang H; Li S; Ye D
Cancer Biol Med; 2024 Feb; 20(12):1047-59. PubMed ID: 38318809
[TBL] [Abstract][Full Text] [Related]
7. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K
Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
[TBL] [Abstract][Full Text] [Related]
8. 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial.
Fontana D; Mari M; Martinelli A; Boccafoschi C; Magno C; Turriziani M; Maymone SS; Cunico SC; Zanollo A; Montagna G; Frongia M; Jacobellis U
Urol Int; 2003; 70(4):316-20. PubMed ID: 12740498
[TBL] [Abstract][Full Text] [Related]
9. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
[TBL] [Abstract][Full Text] [Related]
10. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
[TBL] [Abstract][Full Text] [Related]
11. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
Williams G; Lindsay S; Bowsher WG
Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
[TBL] [Abstract][Full Text] [Related]
12. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer.
Sharifi R; Knoll LD; Smith J; Kramolowsky E
Urology; 1998 Feb; 51(2):271-6. PubMed ID: 9495710
[TBL] [Abstract][Full Text] [Related]
13. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
[TBL] [Abstract][Full Text] [Related]
14. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
Dijkman GA; Fernandez del Moral P; Plasman JW; Pull HC; van der Meijden AP; Debruyne FM; Hutchinson FG; Furr BJ
Eur Urol; 1990; 18 Suppl 3():22-5. PubMed ID: 2151271
[TBL] [Abstract][Full Text] [Related]
15. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
Bong GW; Clarke HS; Hancock WC; Keane TE
Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
[TBL] [Abstract][Full Text] [Related]
16. Comparison of efficacy and safety of 1- and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer.
Ishizuka O; Nishizawa O; Nishizawa S; Satoh T; Wajiki M; Kiyokawa H; Inoue Y; Kobayashi S; Mizusawa H; Nakagawa T
Int J Clin Oncol; 2013 Jun; 18(3):524-30. PubMed ID: 22552359
[TBL] [Abstract][Full Text] [Related]
17. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].
Tsukagoshi S
Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959
[TBL] [Abstract][Full Text] [Related]
18. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial.
Zinner NR; Bidair M; Centeno A; Tomera K
Urology; 2004 Dec; 64(6):1177-81. PubMed ID: 15596193
[TBL] [Abstract][Full Text] [Related]
19. A new extra long acting depot preparation of the LHRH analogue Zoladex. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer.
Dijkman GA; del Moral PF; Plasman JW; Kums JJ; Delaere KP; Debruyne FM; Hutchinson FJ; Furr BJ
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):933-6. PubMed ID: 2149507
[TBL] [Abstract][Full Text] [Related]
20. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
